Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422339 | 0.93 | KMT2A (0.43) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL8606944 | 0.88 | KMT2A (0.48) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL19633062 | 0.87 | L3MBTL1 (0.46) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL30966206 | 0.86 | L3MBTL1 (0.42) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL31677356 | 0.86 | L3MBTL1 (0.42) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL20063081 | 0.86 | L3MBTL1 (0.54) | KMT2AL3MBTL1RAB9AALDH1A1CYP2C19 | |
| SCHEMBL25281082 | 0.86 | L3MBTL1 (0.45) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL20209476 | 0.86 | TPSAB1 (0.49) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL793840 | 0.86 | L3MBTL1 (0.45) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 | |
| SCHEMBL31515414 | 0.86 | L3MBTL1 (0.45) | KMT2AFABP5FABP7L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2002040466-A2 | AMIDOALKYL-PIPERIDINE AND AMIDOALKYL-PIPERAZINE DERIVATIVES FOR TREATING OF NERVOUS SYSTEMS DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-0800516-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORP (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1115731-A2 | NOVEL PYRANOSES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000014097-A2 | NOVEL PYRANOSES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-16 | — | — | WO | disclosed |
| US-5866592-A | Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same | NIPPON STEEL CORPORATION (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0800516-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885FABP5 1093/4885FABP7 2453/4885 |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | KMT2A 2815/4885FABP5 826/4885FABP7 78/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885FABP5 1093/4885FABP7 2453/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | KMT2A 2815/4885FABP5 826/4885FABP7 78/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885FABP5 1093/4885FABP7 2453/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | KMT2A 2815/4885FABP5 826/4885FABP7 78/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885FABP5 1093/4885FABP7 2453/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | KMT2A 2815/4885FABP5 826/4885FABP7 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.